IGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.

ABSTRACT:

Introduction

The treatment of patients with type 2 diabetes uncontrolled on basal insulin and oral glucose-lowering drugs was investigated previously in the LixiLan-L trial. In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks. In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.

Methods

This post hoc analysis of the LixiLan-L trial included bo

SUBMITTER: Niemoeller E 

PROVIDER: S-EPMC5801222 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature